Gilead’s Exchange Of Discounts For Access Causes HCV Market Uncertainty
Executive Summary
With one analyst declaring the hepatitis C market opportunity “capped,” opinions are mixed on Gilead’s payer strategy of trading steeper discounts for greater patient access.